NUWE
Nuwellis Inc
NASDAQ: NUWE · HEALTHCARE · MEDICAL DEVICES
$1.89
-2.07% today
Updated 2026-07-29
Market cap
$177950.00
P/E ratio
0.04
P/S ratio
0.02x
EPS (TTM)
$44.95
Dividend yield
—
52W range
$2 – $378
Volume
2.3M
WallStSmart proprietary scores
37
out of 100
Grade: D
Sell
Investment rating
4.0
Growth
C5.5
Quality
C+2.0
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-73.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$11.00
+482.01%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Revenue growth 26.20% QoQ
+ Debt/equity 0.09x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -73.91 — distress zone
- Thin margins at -217.20%
- Negative free cash flow $-3.14M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $8.54M | $8.86M | $8.74M | $8.27M | $8.77M |
| Net income | $-14.53M | $-20.21M | $-11.16M | $-17.52M | $-4.34M |
| EPS | — | — | — | — | $44.95 |
| Free cash flow | $-15.27M | $-18.18M | $-9.65M | $-10.90M | $-3.14M |
| Profit margin | -170.02% | -227.99% | -127.75% | -211.86% | -217.20% |
Peer comparison
Smart narrative
Nuwellis Inc trades at $1.89. representing a P/E of 0.04x trailing earnings. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -73.91, it sits in the distress. TTM revenue stands at $8.77M. with profit margins at -217.20%.
Frequently asked questions
What is Nuwellis Inc's stock price?
Nuwellis Inc (NUWE) trades at $1.89, on a P/E of 0.0x and a P/S of 0.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Nuwellis Inc overvalued?
Nuwellis Inc carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Nuwellis Inc (NUWE)?
The 12-month analyst consensus target is $11.00, about 482.0% above the current $1.89. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Nuwellis Inc's revenue?
Nuwellis Inc's trailing twelve-month revenue is $8.77M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Nuwellis Inc's Altman Z-Score is -73.91, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.02x
ROE-657.54%
Beta0.30
50D MA$10.63
200D MA$56.16
Shares out0.00B
Float0.00B
Short ratio—
Avg volume2.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—